Article
Exploiting signaling rewiring in cancer cells with co-existing oncogenic drivers.
Molecular oncology - 1 Nov 2023
Chiarle Roberto, Ambrogio Chiara
Abstract excerpt
The development of tailored therapies designed to specifically target driver oncogenes has initiated a revolutionary era in cancer biology. The availability of a growing number of selective inhibitors has generated novel experimental and clinical paradigms. These represent an opportunity and a challenge for researchers and clinicians to delve deeper into the intricate dynamics of cancer development and response...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
